2013
The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor
Podurgiel S, Nunes E, Yohn S, Barber J, Thompson A, Milligan M, Lee C, López-Cruz L, Pardo M, Valverde O, Lendent C, Baqi Y, Müller C, Correa M, Salamone J. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: Implications for pharmacological models of parkinsonian tremor. Neuroscience 2013, 250: 507-519. PMID: 23867769, DOI: 10.1016/j.neuroscience.2013.07.008.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic Uptake InhibitorsAnimalsCatalepsyData Interpretation, StatisticalDisease Models, AnimalDose-Response Relationship, DrugJawMaleMiceMice, KnockoutMotor ActivityMovementParkinsonian DisordersProto-Oncogene Proteins c-fosRatsRats, Sprague-DawleyReceptor, Adenosine A2ATetrabenazineTremorVesicular Monoamine Transport ProteinsXanthinesConceptsTremulous jaw movementsVentrolateral neostriatumC-fos expressionMSX-3Receptor transmissionAdenosine A2A antagonist MSX-3A2A receptor knockout miceParkinsonian tremorC-Fos-positive cellsAbility of tetrabenazineParkinsonian side effectsVesicular monoamine storageJaw movementsReceptor knockout miceAdenosine A2A receptorsOral tremorWild-type controlsPharmacological antagonismStriatal dopamineLocomotor suppressionMotor effectsCD1 miceRodent modelsKnockout miceSide effects
2010
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior
Randall P, Vemuri V, Segovia K, Torres E, Hosmer S, Nunes E, Santerre J, Makriyannis A, Salamone J. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacology Biochemistry And Behavior 2010, 97: 179-184. PMID: 20713079, PMCID: PMC3522179, DOI: 10.1016/j.pbb.2010.07.021.Peer-Reviewed Original ResearchConceptsAppetite suppressant drugsFood-motivated behaviorHigh-fat dietCentral nervous systemFood-reinforced behaviorSame dose rangeCB1 inverse agonistsUndesirable side effectsChow intakeIntraperitoneal administrationAM6545CB1 receptorsAppetite suppressantsCannabinoid antagonistFood intakeHigh doseSide effectsNervous systemPoor penetrabilityInverse agonistNeutral antagonistsDose rangeMild suppressionIntakeAntagonist